Pharmaceutical Development Executive Jeffrey Kasher, Ph.D., Joins DrugDev As Chairman Of Advisory Board

KING OF PRUSSIA, Pa. & LONDON--(BUSINESS WIRE)--DrugDev continues to attract pharmaceutical industry visionaries to join its mission of developing innovative clinical technology solutions to help sponsors, CROs and sites do more trials together. Today, the company announced Jeffrey Kasher, Ph.D., has joined as Chairman of the DrugDev Advisory Board, a distinguished team of current and former clinical research executives from many of the leading pharmaceutical companies in the world.

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.